The primary objective of the City of Hope Cancer Center Lymphoma SPORE Developmental Research Program is to support high quality, innovative translational research projects that are not yet sufficiently mature for full program status despite having outstanding potential. This objective will be accomplished through the Developmental Research Program's capacity to identify conceptually novel and innovative hypothesis-driven projects spanning the spectrum of basic to medical science and clinical research pertaining to lymphoma, to provide fiscal support to allow sufficient development of these projects for subsequent funding as full SPORE projects or as independent projects funded by an independent peer-reviewed mechanism, and to provide intellectual/practical advice to Developmental Project leaders and foster collaborations to facilitate the translational process. This program will impart flexibility to the SPORE, allowing it to respond quickly to the latest developments in translational lymphoma research and to take maximal advantage of new technologies, opportunities for new collaborations, and novel ideas and approaches. Funds in this program can also be used to develop a new shared resource or establish a new technology within an existing shared resource, to support short-term collaborations with investigators in other institutions, or to purchase services for the SPORE in response to a recognized need. Outlines of five developmental research projects from investigators within the City of Hope Research community, as well from established collaborators outside the institution, are included to demonstrate the depth and breadth of ongoing research that could be eligible for support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA107399-03
Application #
7291015
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
3
Fiscal Year
2006
Total Cost
$80,824
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Mei, Matthew G; Cao, Thai M; Chen, Lu et al. (2017) Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant 23:1861-1869
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31

Showing the most recent 10 out of 97 publications